DSIP vs Selank

Overview

DSIP (delta sleep-inducing peptide) and selank are both peptides that affect central nervous system function, but target different aspects of brain activity. DSIP is proposed to modulate sleep architecture, while selank is proposed as an anxiolytic. Neither is approved by Western regulatory agencies.

This comparison matters because both peptides are discussed in contexts of stress management and sleep optimization, though they work through different mechanisms.

Key Facts

Aspect	DSIP	Selank
Full Name	Delta Sleep-Inducing Peptide	Selank (TP-7)
Structure	9 amino acids	7 amino acids
Origin	Discovered 1977 (Switzerland)	Developed 1990s (Russia)
Primary Claim	Sleep modulation	Anxiolytic
FDA Status	Not approved	Not approved
Russian Status	Not approved	Approved

Structure Comparison

Aspect	DSIP	Selank
Sequence	Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Amino Acids	9	7
Base Peptide	Unique	Tuftsin analog
Molecular Weight	~849 Da	~751 Da
Natural Occurrence	Found in brain tissue	Synthetic

Mechanism Comparison

Aspect	DSIP	Selank
Primary Target	Sleep centers (proposed)	GABA system
Secondary Effects	Stress response	Immunomodulation
CNS Action	Sleep architecture	Anxiety reduction
Receptor Binding	Unclear	GABAergic modulation

DSIP Proposed Mechanisms

1. Sleep Modulation

   • Proposed to enhance delta wave sleep
   • May affect sleep onset
   • Uncertain mechanism of action

2. Stress Response

   • May modulate cortisol
   • Proposed adaptogenic effects
   • Limited mechanistic data

3. Opioid System

   • Some interaction proposed
   • Not a classical opioid
   • Unclear significance

Note: DSIP’s mechanism remains poorly understood despite decades of research.

Selank Proposed Mechanisms

1. GABAergic Modulation

   • Affects GABA-A receptor function
   • Anxiolytic effects
   • Does not directly bind GABA receptors

2. Monoamine Systems

   • May affect serotonin metabolism
   • Dopamine modulation proposed
   • Norepinephrine effects

3. Tuftsin-Related Effects

   • Based on immunomodulatory peptide
   • May have immune effects
   • Secondary to CNS actions

Evidence Quality

Factor	DSIP	Selank
Human Studies	Few	Some (Russian)
Controlled Trials	Very limited	Limited
Western Peer Review	Minimal	Minimal
Mechanism Clarity	Poor	Moderate
Overall Evidence	Very Low	Low

DSIP Research History

Era	Status
1977-1980s	Initial discovery and enthusiasm
1980s-1990s	Mixed results, declining interest
2000s-present	Limited research, mechanism unclear

Key Issues:

• Initial findings not consistently replicated
• Mechanism never fully elucidated
• No pharmaceutical development
• Limited recent research

Selank Research History

Era	Status
1990s	Development in Russia
2000s	Russian approval
Present	Used in Russia, limited Western research

Key Issues:

• Primarily Russian research
• Limited Western validation
• Methodology questions
• No international approval

Proposed Applications

DSIP Claimed Uses

Use	Evidence Level
Sleep improvement	Very low
Stress reduction	Very low
Pain modulation	Very low
Substance withdrawal	Anecdotal

Selank Approved Uses (Russia Only)

Use	Evidence Level
Generalized anxiety	Low (Russian data)
Asthenic conditions	Low (Russian data)
Cognitive support	Very low
Stress adaptation	Very low

Administration

Aspect	DSIP	Selank
Primary Route	Injection (SC, IV, IM)	Intranasal
Alternative Routes	Intranasal (less studied)	None practical

Administration Convenience

Factor	DSIP	Selank
Ease of Use	Lower (injection)	Higher (nasal spray)
Self-Administration	Possible	Easy
Timing Sensitivity	Yes (sleep-related)	Less critical

Side Effect Profiles

DSIP Reported Effects

Effect	Frequency	Notes
Morning grogginess	Reported	If sleep effect occurs
Headache	Occasional	Uncertain relation
Injection site	Common	If injected
Limited safety data	—	Major concern

Selank Reported Effects

Effect	Frequency	Notes
Nasal irritation	Common	Route-related
Fatigue	Occasional	Sometimes reported
Headache	Occasional	Usually transient
Generally mild	Yes	Per Russian data

Safety Considerations

Factor	DSIP	Selank
Long-term data	None	Limited
Drug interactions	Unknown	Unknown
Contraindications	Unknown	Unknown
Quality concerns	Significant	Significant

Specific Concerns

DSIP:

• Mechanism unknown raises safety questions
• No regulatory safety review
• Very limited human exposure data
• Quality from research sources uncertain

Selank:

• Russian approval based on different standards
• Limited Western safety evaluation
• Unknown long-term effects
• Research chemical quality variable

Regulatory Status

Aspect	DSIP	Selank
FDA Status	Not approved	Not approved
Russian Status	Not approved	Approved (anxiolytic)
European Status	Not approved	Not approved
WADA Status	Not specifically listed	Not specifically listed
Legal Status	Research chemical	Research chemical (outside Russia)

Comparison by Use Case

For Sleep Issues

Factor	DSIP	Selank
Primary target	Yes (claimed)	No (indirect)
Evidence Level	Moderate	Moderate
Mechanism clarity	Poor	N/A

For Anxiety

Factor	DSIP	Selank
Primary target	No (secondary)	Yes (claimed)
Evidence Level	Moderate	Moderate
Approval	None	Russia only

For Stress Management

Factor	DSIP	Selank
Claims	Adaptogenic	Anxiolytic
Evidence Level	Moderate	Moderate
Mechanism	Unclear	GABAergic

Quality and Sourcing

Both peptides face significant quality challenges:

Issue	DSIP	Selank
Regulated sources	None	Russia only
Research chemical quality	Variable	Variable
Testing availability	Limited	Limited
Degradation concerns	Yes	Yes
Purity verification	Difficult	Difficult

Summary

Factor	DSIP	Selank
Structure	9 amino acids	7 amino acids
Primary Target	Sleep	Anxiety
Mechanism Clarity	Poor	Moderate
Evidence Level	Moderate	Moderate
Administration	Injection	Intranasal
Any Approval	No	Russia only
Western Validation	Minimal	Minimal

Key Takeaways

1. Different targets: DSIP for sleep; selank for anxiety
2. Both lack Western approval: Neither FDA nor EMA approved
3. Selank has Russian approval: Used clinically in Russia
4. DSIP mechanism unclear: Despite decades, mechanism not established
5. Evidence is limited for both: No rigorous Western clinical trials
6. Selank is easier to use: Intranasal vs. injection
7. Quality concerns significant: Both available only from unregulated sources
8. Not interchangeable: Different proposed mechanisms and uses
9. Research status only: Neither should be considered validated therapy

---

This comparison is for educational purposes only. Neither peptide is approved by Western regulatory agencies. Selank is approved in Russia only. Products sold as research chemicals have uncertain quality and safety.